| Extracellular vesicles in cancer: cell-to-cell mediators of metastasis A Becker, BK Thakur, JM Weiss, HS Kim, H Peinado, D Lyden Cancer cell 30 (6), 836-848, 2016 | 1683 | 2016 |
| Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation H Zhang, D Freitas, HS Kim, K Fabijanic, Z Li, H Chen, MT Mark, H Molina, ... Nature cell biology 20 (3), 332-343, 2018 | 1351 | 2018 |
| Extracellular vesicle and particle biomarkers define multiple human cancers A Hoshino, HS Kim, L Bojmar, KE Gyan, M Cioffi, J Hernandez, ... Cell 182 (4), 1044-1061. e18, 2020 | 812 | 2020 |
| Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis G Rodrigues, A Hoshino, CM Kenific, IR Matei, L Steiner, D Freitas, ... Nature cell biology 21 (11), 1403-1412, 2019 | 308 | 2019 |
| Identification of a radiosensitivity signature using integrative metaanalysis of published microarray data for NCI-60 cancer cells HS Kim, SC Kim, SJ Kim, CH Park, HC Jeung, YB Kim, JB Ahn, HC Chung, ... BMC genomics 13, 1-10, 2012 | 144 | 2012 |
| Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information S Kim, HS Kim, E Kim, MG Lee, EC Shin, S Paik Annals of Oncology 29 (4), 1030-1036, 2018 | 133 | 2018 |
| Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study S Qin, SL Chan, S Gu, Y Bai, Z Ren, X Lin, Z Chen, W Jia, Y Jin, Y Guo, ... The Lancet 402 (10408), 1133-1146, 2023 | 108 | 2023 |
| Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition HS Kim, M Jung, HN Kang, H Kim, CW Park, SM Kim, SJ Shin, SH Kim, ... Oncogene 36 (23), 3334-3345, 2017 | 89 | 2017 |
| Personalized therapy on the horizon for squamous cell carcinoma of the lung HS Kim, T Mitsudomi, RA Soo, BC Cho Lung cancer 80 (3), 249-255, 2013 | 81 | 2013 |
| Targeting mutant KRAS with CRISPR-Cas9 controls tumor growth W Kim, S Lee, HS Kim, M Song, YH Cha, YH Kim, J Shin, ES Lee, Y Joo, ... Genome research 28 (3), 374-382, 2018 | 71 | 2018 |
| A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair–Deficient/Microsatellite Instability–High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer JH Kim, SY Kim, JY Baek, YJ Cha, JB Ahn, HS Kim, KW Lee, JW Kim, ... Cancer Research and Treatment: Official Journal of Korean Cancer Association …, 2020 | 69 | 2020 |
| Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors HS Kim, SJ Shin, SC Kim, S An, SY Rha, JB Ahn, BC Cho, HJ Choi, ... Supportive Care in Cancer 21, 1751-1759, 2013 | 67 | 2013 |
| Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck HS Kim, HJ Kwon, I Jung, MR Yun, MJ Ahn, BW Kang, JM Sun, SB Kim, ... Clinical Cancer Research 21 (3), 544-552, 2015 | 66 | 2015 |
| Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma J Cheon, C Yoo, JY Hong, HS Kim, DW Lee, MA Lee, JW Kim, I Kim, ... Liver International 42 (3), 674-681, 2022 | 49 | 2022 |
| Tumour extracellular vesicles and particles induce liver metabolic dysfunction G Wang, J Li, L Bojmar, H Chen, Z Li, GC Tobias, M Hu, EA Homan, ... Nature 618 (7964), 374-382, 2023 | 43 | 2023 |
| Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers JW Ahn, HS Kim, JK Yoon, H Jang, SM Han, S Eun, HS Shim, HJ Kim, ... Genome medicine 6, 1-10, 2014 | 42 | 2014 |
| A coding variant in FTO confers susceptibility to thiopurine-induced leukopenia in East Asian patients with IBD HS Kim, JH Cheon, ES Jung, J Park, S Aum, SJ Park, S Eun, J Lee, ... Gut 66 (11), 1926-1935, 2017 | 38 | 2017 |
| Unshielding exosomal RNA unleashes tumor growth and metastasis I Matei, HS Kim, D Lyden Cell 170 (2), 223-225, 2017 | 38 | 2017 |
| Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck KK Huang, KW Jang, S Kim, HS Kim, SM Kim, HJ Kwon, HR Kim, HJ Yun, ... Scientific reports 6 (1), 19552, 2016 | 38 | 2016 |
| Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial JM Llovet, M Kudo, P Merle, T Meyer, S Qin, M Ikeda, R Xu, J Edeline, ... The Lancet Oncology 24 (12), 1399-1410, 2023 | 35 | 2023 |
Soonmyung PaikYonsei University College of MedicineE-mailová adresa ověřena na: yuhs.ac
